

**Reference:** FOI 36160 GLO 11M

**Subject:** Psoriasis and Psoriatic Arthritis Treatments

*I can confirm that the CCG does hold the information requested; please see responses below:*

| QUESTION   | RESPONSE       |
|--|----------------|
| 1. Has a shared care agreement/arrangement been established between the CCG, secondary care and local primary care services (e.g. general practitioners) for the treatment of Psoriasis and Psoriatic Arthritis? |                |
| a. Psoriasis: Y/N  | No             |
| b. Psoriatic Arthritis: Y/N  | No             |
| 2. If you answered 'Yes' to Q1, what are the names and/or roles of the signatories of the shared care agreement?   | Not applicable |
| 3. If you answered 'Yes' to Q1, which of the following medicines can be prescribed within the shared care agreement?   |                |
| 4. How many consultant-led <u>community-based</u> Dermatology or Rheumatology services has your CCG commissioned that treat Psoriasis or Psoriatic Arthritis?  | None           |
| 5. Who/where are these services commissioned from?   | Not applicable |
| 6. Which of the following treatments can be prescribed by these services?  |                |

|   |                       |
|---|-----------------------|
| <p><b>7. How many GPwERs has your CCG commissioned for Dermatology, and Rheumatology?<br/>Please provide the geographical locations of these commissioned services.</b></p> | <p>None</p>           |
| <p><b>8. Are digital services commissioned by the CCG for the management of Dermatology and Rheumatology? Y/N?</b></p>  | <p>Not applicable</p> |
| <p><b>9. If so, please specify the digital services provided? This may include teledermatology services (various levels) and/or virtual clinics.</b></p>                    |                       |

*The information provided in this response is accurate as of 23 July 2020 and has been authorised for release by Marion Andrews-Evans, Executive Nurse and Quality Lead for NHS Gloucestershire CCG.*